Emerging Drug Developer: Itero Biopharmaceuticals

Itero Biopharmaceuticals

The executive team behind the Itero start-up says that high-tech companies can teach biotech a thing or two about more efficient drug development. Specifically, signing up partnership agreements with companies halfway around the world can help move product work, especially when you're out to penetrate the world of biosimilars. There's a lot that Itero won't discuss at this stage, but development strategy is taking center stage. Article

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.